This has led to the initiation of a phase I trial to study the side effects and how well IL13Ralpha2‐CRT T cells work when given alone or together with nivolumab and ipilimumab (PD‐1 AND CTL4A) in GBM patients. This evidence concerns the gene IL13RA2 and glioblastoma.